Cost-Utility Analysis Of Alemtuzumab Versus Natalizumab For The Treatment Of Relapsing-Remitting Multiple Sclerosis- Us Payer Perspective

Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.490
https://www.valueinhealthjournal.com/article/S1098-3015(16)31857-5/fulltext
Title : Cost-Utility Analysis Of Alemtuzumab Versus Natalizumab For The Treatment Of Relapsing-Remitting Multiple Sclerosis- Us Payer Perspective
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)31857-5&doi=10.1016/j.jval.2016.09.490
First page : A431
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 462
Categories :
Tags :
Regions :
ViH Article Tags :